| Chronic Obstructive Airway Disease
Anoro Ellipta vs Dupixent
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Anoro Ellipta vs Dupixent with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDupixent has a higher rate of injection site reactions vs Anoro Ellipta based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Dupixent but not Anoro Ellipta, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Anoro Ellipta
Dupixent
At A Glance
Oral inhalation
Once daily
LAMA/LABA
SC injection
Every 2 weeks
IL-4Ra antagonist
Indications
- Chronic Obstructive Airway Disease
- Dermatitis, Atopic
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- Eosinophilic esophagitis
- Prurigo nodularis
- Chronic Obstructive Airway Disease
- Chronic Spontaneous Urticaria
- Bullous pemphigoid
- Allergic Fungal Rhinosinusitis
Dosing
Chronic Obstructive Airway Disease 62.5 mcg umeclidinium and 25 mcg vilanterol (1 actuation of ANORO ELLIPTA 62.5/25 mcg) once daily by oral inhalation; do not use more than 1 time every 24 hours.
Dermatitis, Atopic Adults: 600 mg initial dose, then 300 mg SC Q2W; pediatric patients 6 months to 5 years: weight-based Q4W without loading dose; pediatric patients >=6 years: weight-based loading dose then Q2W or Q4W.
Asthma Adults and pediatric >=12 years: 400 mg or 600 mg loading dose, then 200 mg or 300 mg SC Q2W; pediatric 6-11 years: weight-based Q2W or Q4W without loading dose.
Chronic rhinosinusitis with multiple nasal polyps 300 mg SC Q2W for adults and pediatric patients >=12 years.
Eosinophilic esophagitis SC weight-based dosing for patients >=1 year weighing >=15 kg: 200 mg Q2W (15 to <30 kg), 300 mg Q2W (30 to <40 kg), or 300 mg weekly (>=40 kg).
Prurigo nodularis Adults: 600 mg initial dose, then 300 mg SC Q2W.
Chronic Obstructive Airway Disease Adults: 300 mg SC Q2W.
Chronic Spontaneous Urticaria Adults: 600 mg initial dose, then 300 mg SC Q2W; pediatric 12-17 years: weight-based 400 mg or 600 mg loading, then 200 mg or 300 mg Q2W.
Bullous pemphigoid Adults: 600 mg initial dose, then 300 mg SC Q2W in combination with a tapering course of oral corticosteroids.
Allergic Fungal Rhinosinusitis Adults: 300 mg SC Q2W; pediatric 6-17 years: weight-based Q2W or Q4W (15 to <30 kg: 300 mg Q4W; 30 to <60 kg: 200 mg Q2W; >=60 kg: 300 mg Q2W).
Contraindications
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to umeclidinium, vilanterol, or any excipient
- Use of a long-acting beta2-adrenergic agonist (LABA) without an inhaled corticosteroid (ICS) in patients with asthma
- Known hypersensitivity to dupilumab or any excipients of DUPIXENT
Adverse Reactions
Most common (>=1%) Pharyngitis, sinusitis, lower respiratory tract infection, constipation, diarrhea, pain in extremity, muscle spasms, neck pain, chest pain
Serious Serious asthma-related events (hospitalizations, intubations, death), paradoxical bronchospasm, cardiovascular effects, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Palpitations, blurred vision, eye pain, glaucoma, increased intraocular pressure, anaphylaxis, angioedema, urticaria, dysgeusia, tremor, anxiety, dysuria, urinary retention, dysphonia
Most common (>=1%) Injection site reactions, conjunctivitis, oral herpes, blepharitis, keratitis, eye pruritus, other herpes simplex virus infection, dry eye
Serious Hypersensitivity reactions, conjunctivitis and keratitis, psoriasis, arthralgia and psoriatic arthritis, parasitic (helminth) infections
Postmarketing Angioedema, psoriatic arthritis, facial skin reactions (erythema, rash, scaling, edema, papules, pruritus, burning, pain), new-onset psoriasis, vasculitis
Pharmacology
Umeclidinium is a long-acting muscarinic antagonist (LAMA) that inhibits M3 receptors in airway smooth muscle to produce bronchodilation; vilanterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase to increase cyclic AMP, relaxing bronchial smooth muscle and inhibiting mediator release from mast cells.
Dupilumab is a human monoclonal IgG4 antibody that inhibits IL-4 and IL-13 signaling by binding to the IL-4Ra subunit shared by the IL-4 and IL-13 receptor complexes, blocking cytokine-induced inflammatory responses including release of proinflammatory cytokines, chemokines, nitric oxide, and IgE.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Anoro Ellipta
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (11/12)
Dupixent
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (12/12) · Qty limit (2/12)
UnitedHealthcare
Anoro Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (6/8)
Dupixent
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (6/8)
Humana
Anoro Ellipta
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (1/3)
Dupixent
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Anoro Ellipta.
Cost estimate not availableHealthWell Foundation: Asthma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Final cost depends on formulary coverage
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Anoro ElliptaView full Anoro Ellipta profile
DupixentView full Dupixent profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.